Dr. Constance Smith-hicks, M.D.
Child Neurology (Neurology with Special Qualifications in Child Neurology Physician)
200 N Wolfe St, Suite 2147
Baltimore, MD 21287
Who else practices at this address →
Baltimore city includes primary care (36% of residents) shortage areas. About shortage areas
At a glance
- Medical school
- Columbia University College of Physicians and Surgeons (2000)
- Years since graduation
- 26
- In the NPI registry since
- 2007
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2000Medical school: Columbia University College of Physicians and Surgeons
- 2007Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Neurology with Special Qualifications in Child Neurology Physician primary
MD license D65871 -
Neurology Physician
MD license D65871
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Kennedy Krieger Institute Baltimore, MD
Medical groups
- Kennedy Krieger Associates (73 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Daybue (trofinetide) | 52 |
| Fluoxetine Hcl Other prescribers in Baltimore, MD | 12 |
| Levetiracetam Other prescribers in Baltimore, MD | 11 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 2 companies reported 11 payments worth $3,867 in total to this clinician.
| Acadia Pharmaceuticals Inc | $2,411 |
|---|---|
| Ionis Pharmaceuticals, Inc. | $1,456 |
| Consulting Fee | $1,650 |
|---|---|
| Travel and Lodging | $1,264 |
| Compensation for services other than consulting (speaking, faculty) | $600 |
| Food and Beverage | $353 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Acadia Pharmaceuticals Inc Feb 24, 2025 | Consulting Fee DAYBUE · RETT SYNDROME | $1,650 |
| Acadia Pharmaceuticals Inc Dec 29, 2025 | Compensation for services other than consulting (speaking, faculty) DAYBUE · RETT SYNDROME | $600 |
| Ionis Pharmaceuticals, Inc. Sep 18, 2025 | Travel and Lodging travel to NASHVILLE, TN · in-kind | $553 |
| Ionis Pharmaceuticals, Inc. Sep 18, 2025 | Travel and Lodging travel to NASHVILLE, TN · in-kind | $512 |
| Ionis Pharmaceuticals, Inc. Sep 18, 2025 | Travel and Lodging travel to NASHVILLE, TN · in-kind | $149 |
| Ionis Pharmaceuticals, Inc. Sep 19, 2025 | Travel and Lodging travel to NASHVILLE, TN · in-kind | $50.00 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 1 industry-funded study in 2025, from 1 company. The companies reported $23,100 in research payments for these studies, mostly to the institutions running them.
- Study of Carbetocin Nasal Spray for the Treatment of Hyperphagia in Prader-Willi Syndrome
Acadia Pharmaceuticals Inc · Completed · NCT06173531
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.